U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1 U.S. Contraceptive Market: Methodology and Scope
                   1.1 Market Segmentation & Scope
                       1.1.1 Estimates And Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased Database
                       1.3.2 GVR’s Internal Database
                       1.3.3 SSecondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details of Primary Research
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis
                       1.6.2 Volume Price Analysis
                   1.7 List of Secondary Sources
                   1.8 List of Primary Sources
                   1.9 List of Abbreviations
                   1.10 Objectives
                       1.10.1 Objective 1
                       1.10.2 Objective 2
                       1.10.3 Objective 3
Chapter 2 U.S. Contraceptive Market: Executive Summary
                   2.1 Market Outlook
                   2.2 Segment Outlook
                       2.2.1 Product
                   2.3 Competitive Insights
Chapter 3 U.S. Contraceptive Market: Variables, Trends, & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent market outlook
                       3.1.2 Related/Ancillary market outlook
                   3.2 Market Dynamics
                       3.2.1 Market driver analysis
                           3.2.1.1 Rapid technological advancements
                           3.2.1.2 Increasing initiatives by social organizations to improve access to condoms
                           3.2.1.3 Rising publicly funded family planning services
                       3.2.2 Market restraint analysis
                           3.2.2.1 Increasing geriatric population and rising prevalence of infertility
                           3.2.2.2 Adverse effects associated with the use of contraceptive drugs and devices
                   3.3 Business Environment Analysis Tools
                       3.3.1 PESTEL analysis
                           3.3.1.1 Political & legal landscape
                           3.3.1.2 Economic & social landscape
                           3.3.1.3 Technological landscape
                       3.3.2 Porter’s Five Forces Analysis
                           3.3.2.1 Competitive rivalry - High
                           3.3.2.2 Bargaining power of suppliers - Moderate
                           3.3.2.3 Bargaining power of buyers - Moderate
                           3.3.2.4 Threat of new entrants - High
                           3.3.2.5 Threat of substitutes - Moderate
                   3.4 Penetration & Growth Prospect Mapping
                       3.4.1 Analysis
                   3.5 Pipeline Analysis
                   3.6 Regulatory & Reimbursement Framework
                       3.6.1 Regulatory Scenario
                       3.6.2 Reimbursement Framework
                   3.7 Impact of COVID - 19: Qualitative Analysis
Chapter 4 U.S. Contraceptive Market: Product Analysis
                   4.1 U.S. Contraceptive Market Share Analysis, 2022- 2030
                   4.2 U.S. Contraceptive Product Market: Segment Dashboard
                   4.3 Market Size & Forecasts and Trend Analysis, 2017 to 2030 for the Product Segment
                       4.3.1 Pills
                           4.3.1.1 Pills market, 2017 - 2030 (USD Billion)
                       4.3.2 Intrauterine Device (IUD)
                           4.3.2.1 Intrauterine device market, 2017 - 2030 (USD Billion)
                           4.3.2.2 Hormonal IUD
                               4.3.2.2.1 Hormonal IUD market, 2017 - 2030 (USD Billion)
                           4.3.2.3 Nonhormonal IUD
                               4.3.2.3.1 Nonhormonal IUD market, 2017 - 2030 (USD Million)
                       4.3.3 Condoms
                           4.3.3.1 Condoms market, 2017 - 2030 (USD Billion)
                           4.3.3.2 Male Condoms
                               4.3.3.2.1 Male Condoms market, 2017 - 2030 (USD Million)
                           4.3.3.3 Female Condoms
                               4.3.3.3.1 Female Condoms market, 2017 - 2030 (USD Million)
                       4.3.4 Vaginal Ring
                           4.3.4.1 Vaginal ring market, 2017 - 2030 (USD Billion)
                       4.3.5 Subdermal Implants
                           4.3.5.1 Subdermal implants market, 2017 - 2030 (USD Billion)
                       4.3.6 Injectable
                           4.3.6.1 Injectable market, 2017 - 2030 (USD Billion)
                       4.3.7 Others
                           4.3.7.1 Others market, 2017 - 2030 (USD Billion)
Chapter 5 Competitive Analysis
                   5.1 Recent Developments & Impact Analysis, by Key Market Participants
                   5.2 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players)
                   5.3 Major Deals & Strategic Alliances Analysis
                       5.3.1 Mergers & acquisitions and joint ventures
                       5.3.2 Licensing & partnership and technology collaborations
                   5.4 Vendor Landscape
                       5.4.1 List of Players in the U.S. Contraceptive Market
                       5.4.2 Company Market Position Analysis
                   5.5 Company Profiles
                       5.5.1 Church & Dwight Co., Inc.
                           5.5.1.1 Company overview
                           5.5.1.2 Financial performance
                           5.5.1.3 Product benchmarking
                           5.5.1.4 Strategic initiatives
                           5.5.1.5 SWOT analysis
                       5.5.2 Reckitt Benckiser Group plc
                           5.5.2.1 Company overview
                           5.5.2.2 Financial performance
                           5.5.2.3 Product benchmarking
                           5.5.2.4 Strategic initiatives
                           5.5.2.5 SWOT analysis
                       5.5.3 Veru, Inc.
                           5.5.3.1 Company Overview
                           5.5.3.2 Financial performance
                           5.5.3.3 Product benchmarking
                           5.5.3.4 Strategic initiatives
                           5.5.3.5 SWOT Analysis
                       5.5.4 Organon Group of Companies
                           5.5.4.1 Company overview
                           5.5.4.2 Financial performance
                           5.5.4.3 Product benchmarking
                           5.5.4.4 Strategic initiative
                           5.5.4.5 SWOT analysis
                       5.5.5 Pfizer, Inc.
                           5.5.5.1 Company overview
                           5.5.5.2 FINANCIAL PERFORMANCE
                           5.5.5.3 Product benchmarking
                           5.5.5.4 Strategic initiatives
                           5.5.5.5 SWOT analysis
                       5.5.6 Teva Pharmaceutical Industries Ltd.
                           5.5.6.1 Company overview
                           5.5.6.2 Financial performance
                           5.5.6.3 Strategic initiatives
                           5.5.6.4 SWOT analysis
                       5.5.7 The Cooper Companies, Inc.
                           5.5.7.1 Company overview
                           5.5.7.2 Financial performance
                           5.5.7.3 Product benchmarking
                           5.5.7.4 Strategic initiative
                           5.5.7.5 SWOT analysis
                       5.5.8 Mayer Laboratories, Inc.
                           5.5.8.1 Company overview
                           5.5.8.2 Product benchmarking
                       5.5.9 Agile Therapeutics
                           5.5.9.1 Company overview
                           5.5.9.2 Financial performance
                           5.5.9.3 Product benchmarking
                           5.5.9.4 Strategic initiatives
                           5.5.9.5 SWOT analysis
                       5.5.10 TherapeuticsMD, Inc.
                           5.5.10.1 Company overview
                           5.5.10.2 Financial performance
                           5.5.10.3 Product benchmarking
                           5.5.10.4 Strategic initiative
                           5.5.10.5 SWOT analysis
                       5.5.11 Bayer AG
                           5.5.11.1 Company overview
                           5.5.11.2 Financial performance
                           5.5.11.3 Product benchmarking
                           5.5.11.4 Strategic initiatives
                           5.5.11.5 SWOT analysis
                       5.5.12 Afaxys, Inc.
                           5.5.12.1 Company overview
                           5.5.12.2 Product benchmarking
                           5.5.12.3 Strategic initiatives
                           5.5.12.4 SWOT analysis
                       5.5.13 Mithra Pharmaceuticals
                           5.5.13.1 Company overview
                           5.5.13.2 Financial performance
                           5.5.13.3 Product benchmarking
                           5.5.13.4 Strategic initiatives
                           5.5.13.5 SWOT analysis
                       5.5.14 Abbvie
                           5.5.14.1 Company overview
                           5.5.14.2 Financial performance
                           5.5.14.3 Product benchmarking
                           5.5.14.4 Strategic initiatives
                           5.5.14.5 SWOT analysis
Chapter 6 Recommendations
                   6.1 KOL Comments
                   6.2 Recommendations

List of Tables

1. List of secondary sources
2. List of abbreviations
3. Contraceptive methods and associated side effects
4. Classification of contraceptives by the U.S. FDA
5. States that have expanded on contraceptive coverage guarantee in the Affordable Care Act
6. Types of oral contraceptives, composition, and regimen
7. List of intrauterine devices currently available in the U.S.
8. Types of male condom variants
9. U.S. contraceptive market, 2017 - 2030 (USD Million)
10. U.S. condom market, by product, 2017 - 2030 (USD Million)
11. U.S. Intrauterine Devices (IUD) Market, by type, 2017 - 2030 (USD Million)

List of Figures

1. Market research process
2. Data triangulation techniques
3. Primary research pattern
4. Market research approaches
5. Value-chain-based sizing & forecasting
6. QFD modeling for market share assessment
7. Market formulation & validation
8. Market outlook, 2021 (USD Million)
9. Market trends & outlook
10. Market driver relevance analysis (Current & future impact)
11. Market restraint relevance analysis (Current & future impact)
12. Penetration & growth prospect mapping
13. U.S. contraceptive product market share analysis, 2021 - 2030 (USD Billion)
14. U.S. contraceptive product market: Segment dashboard
15. Pills market, 2017 - 2030 (USD Billion)
16. Intrauterine device market, 2017 - 2030 (USD Billion)
17. Hormonal IUD market, 2017 - 2030 (USD Billion)
18. Nonhormonal IUD market, 2017 - 2030 (USD Billion)
19. Condoms market, 2017 - 2030 (USD Billion)
20. Male condoms market, 2017 - 2030 (USD Billion)
21. Female condoms market, 2017 - 2030 (USD Billion)
22. Vaginal ring market, 2017 - 2030 (USD Billion)
23. Subdermal implants market, 2017 - 2030 (USD Billion)
24. Injectable market, 2017 - 2030 (USD Billion)
25. Others market, 2017 - 2030 (USD Billion)
26. Impact analysis by key market participants
27. Strategy framework / Competition categorization
28. Company market position analysis